(Q51726426)

10 April 2018

title

Antibiotic treatment of constipation-predominant irritable bowel syndrome. (English)

1 reference

10 April 2018

1

Mark Pimentel

1 reference

10 April 2018

Christopher Chang

2

1 reference

10 April 2018

Kathleen Shari Chua

3

1 reference

10 April 2018

James Mirocha

4

1 reference

10 April 2018

John DiBaise

5

1 reference

10 April 2018

Satish Rao

6

1 reference

10 April 2018

Meridythe Amichai

7

1 reference

10 April 2018

publication date

1 May 2014

1 reference

10 April 2018

Digestive Diseases and Sciences

published in

1 reference

10 April 2018

volume

59

1 reference

10 April 2018

issue

6

1 reference

10 April 2018

page(s)

1278-1285

1 reference

10 April 2018

The burden of selected digestive diseases in the United States.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3157-8

Functional bowel disorders and functional abdominal pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3157-8

Postinfectious irritable bowel syndrome--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3157-8

Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3157-8

Abnormal breath testing in IBS: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3157-8

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3157-8

The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3157-8

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3157-8

Methane on breath testing is associated with constipation: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3157-8

Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3157-8

The degree of breath methane production in IBS correlates with the severity of constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3157-8

Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3157-8

Methanobrevibacter smithii Is the Predominant Methanogen in Patients with Constipation-Predominant IBS and Methane on Breath

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3157-8

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3157-8

Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24788320

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24788320

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10620-014-3157-8

1 reference

10 April 2018

1 reference

10 April 2018